You are here » Home » Companies » Company Overview » Cipla Ltd

Cipla Ltd.

BSE: 500087 Sector: Health care
NSE: CIPLA ISIN Code: INE059A01026
BSE 16:01 | 27 Mar 2018 Cipla Ltd
NSE 05:30 | 01 Jan 1970 Cipla Ltd
OPEN 550.70
PREVIOUS CLOSE 540.75
VOLUME 377007
52-Week high 663.00
52-Week low 479.00
P/E 34.43
Mkt Cap.(Rs cr) 43,717
Buy Price 0.00
Buy Qty 0.00
Sell Price 0.00
Sell Qty 0.00
OPEN 550.70
CLOSE 540.75
VOLUME 377007
52-Week high 663.00
52-Week low 479.00
P/E 34.43
Mkt Cap.(Rs cr) 43,717
Buy Price 0.00
Buy Qty 0.00
Sell Price 0.00
Sell Qty 0.00

Cipla Ltd. (CIPLA) - Chairman Speech

Company chairman speech

FROM THE CHAIRMAN

Dear Shareholders

I would like to take this opportunity to reiterate some fundamental values of yourCompany. For Cipla ensuring access to medicines at affordable prices is essential. Mostleading countries have realised that despite government support medicines are becomingincreasingly more expensive and therefore difficult to buy. This present trend offers anopportunity for a pharmaceutical company like Cipla. At the same time it places a greatresponsibility on us to supply reliable good quality medicines on a long-term sustainablebasis. We need to demonstrate clearly our willingness to promote affordable medicines sothat no one should be denied medication. Companies like ours must promote efficient andwell-run businesses but at the same time have a humanitarian approach to healthcare. Weare one of the few industries directly involved in prolonging and saving lives.

We have always believed that free competition is the only way to ensure fair prices andbetter availability of drugs. Over the years Cipla has overcome innumerable hurdles inmany areas and we will continue to navigate the path ahead as best possible. We stronglybelieve that there should be no monopolies in healthcare; and in that context Indiashould adopt a pragmatic Intellectual Property Rights (IPR) policy including in-licensingwithin the present framework of our international obligations.

Many countries such as Brazil Thailand Indonesia and Malaysia have already introducedcompulsory licensing provisions. The Republic of South Africa is seriously reconsideringtheir position on IPR in order to promote affordable healthcare. India must also examinethe monopoly position of drugs and build safeguards to ensure that this does not happen.India has always stood for the promotion of knowledge and consideration for the greatergood. Both our nation and our Company have deep-rooted foundations based on human values.We sincerely believe that Cipla has the opportunity to show this to the world.

Dr. Y.K. Hamied